GENEVA ACUFF: Open Payments
NPI 1497327936 · ABINGDON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,590 in 136 payments from 18 companies in 2025. Trend: 2023 $1,480 · 2024 $2,029 · 2025 $3,590
Food & beverage: $2,627Consulting: $900Education: $63
| Company | Payments | Amount |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | 7 | $1,104 |
| GENZYME CORPORATION | 10 | $439 |
| UCB, Inc. | 16 | $366 |
| Regeneron Healthcare Solutions, Inc. | 14 | $322 |
| Galderma Laboratories, L.P. | 11 | $264 |
| Janssen Biotech, Inc. | 26 | $263 |
| Novartis Pharmaceuticals Corporation | 13 | $198 |
| ABBVIE INC. | 16 | $194 |
| Organon LLC | 6 | $101 |
| Lilly USA, LLC | 3 | $61 |
Products named: Zoryve, DUPIXENT, Bimzelx, TREMFYA, NEMLUVIO, COSENTYX, SKYRIZI, RINVOQ.
Industry payments across MD — which companies pay providers there.
